Early Electrical Stimulation to Prevent Complications in the Arm Post-stroke - a Feasibility Study (ESCAPS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02324634 |
Recruitment Status : Unknown
Verified May 2017 by University of Nottingham.
Recruitment status was: Active, not recruiting
First Posted : December 24, 2014
Last Update Posted : May 5, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Stroke | Device: NeuroTrac Rehab dual channel device | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Masking Description: | As this is a feasibility RCT, the outcome assessor has not been masked to treatment but would be in a subsequent pilot and definitive trial. |
Primary Purpose: | Treatment |
Official Title: | Early Electrical Stimulation to the Wrist Extensors and Wrist Flexors to Prevent the Post-stroke Complications of Pain and Contractures in the Paretic Arm - a Feasibility Study |
Actual Study Start Date : | June 1, 2015 |
Estimated Primary Completion Date : | November 2017 |
Estimated Study Completion Date : | November 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: ES intervention
Electrical stimulation (ES) twice a day, 5 days a week, for 3 months
|
Device: NeuroTrac Rehab dual channel device
ES intervention twice a day, 5 days a week, for 3 months applied to the wrist extensors and wrist flexors. The therapist will identify the motor points for the forearm flexors and the extensors, and will place an electrode on these motor points using sticky pads. They will then connect the electrodes to the respective channels in the electrical stimulator. The ES will be set to deliver a 450μs pulse at a frequency of 40-60Hz (as per patient convenience). The intensity of the current will be increased to produce an alternating contraction of the flexors and extensors using a flex-hold-extend-hold pattern. A single stimulation and hold cycle will last 20 seconds and this will be cyclically repeated for 30 minutes after which the device can be removed.
Other Name: Electrical stimulation rehabilitation intervention |
No Intervention: Control
Usual care only
|
- Feasibility of the trial design [ Time Frame: 12 months ]Recruitment rates: No./% of participants recruited within 72 hours post-stroke; and time post-stroke that participants received their first treatment; Recruitment strategy: No./% of patients screened, No./% eligible and approached, No./% who consented, No./% excluded after screening; Completion rates: No./% of participants who completed the intervention; No./% who completed the 3, 6 and 12 month follow-up assessments; Feasibility of delivering the intervention: No./% of participants who received ES twice a day, 5 days a week whilst in hospital, and No./% who continued with the treatment regime after discharge. Mean, min and max no. of ES treatments that participants received during the 3 month intervention period; Recruitment of patients lacking mental capacity to consent for themselves: Consultee consent rates (No./% of patients unable to give informed consent, and no. consented by a consultee, no. of consultees who declined consent)
- Tolerability [ Time Frame: 12 months ]Proportion of participants who withdraw or decline intervention; Record of interventions declined and why.
- Integrity of the study protocol [ Time Frame: 12 months ]Measured by examining how many participants are able to complete the study, % of missing data, and % of people who completed each of the outcome measures at 3, 6 and 12 month follow-up, calculation of the cost of running the study.
- NIHSS score [ Time Frame: 0, 3, 6, 12 months ]Neurological outcome and degree of recovery from stroke
- Barthel ADL Index score and modified Rankin Score [ Time Frame: 0, 3, 6, 12 months ]Independence (functional ability) in basic daily activities
- Scale of Pain Intensity (SPIN) [ Time Frame: 0, 3, 6, 12 months ]Pain in the affected arm
- Muscle contractures (reduction in range of movement and spasticity) [ Time Frame: 0, 3, 6, 12 months ]Muscle contractures (reduction in range of movement and spasticity) will be monitored by measuring muscle activity during assessments using Biometrics equipment
- Action Research Arm Test (ARAT) [ Time Frame: 0, 3, 6, 12 months ]Arm function
- Stroke Specific Quality of Life Scale (SS-QOL) [ Time Frame: 0, 3, 6, 12 months ]Stroke related quality of life
- EuroQoL-5D (EQ-5D) [ Time Frame: 0, 3, 6, 12 months ]Health status
- Patient resource questionnaire [ Time Frame: 0, 3, 6, 12 months ]A measure of resource use and health related costs
- Caregiver Strain Index (CSI) [ Time Frame: 0, 3, 6, 12 months ]Carer strain
- Nottingham Extended ADL (NEADL) [ Time Frame: 0 months ]Pre-morbid functional state
- The Montreal Cognitive Assessment (MoCA) [ Time Frame: 0 months ]Cognitive status at baseline
- Patient resource use (cost) questionnaire [ Time Frame: 0, 3, 6, 12 months ]A questionnaire to measure resource use and associated health costs.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Main feasibility RCT eligibility criteria:
Inclusion Criteria:
- Patients with a confirmed clinical diagnosis of stroke AND it is their first stroke event to affect their upper limb
- Patients aged 18 years or over
- Impaired arm movement and strength resulting in reduced function, caused specifically by the stroke. (as determined by the arm subsection score of the National Institute for Health Stroke Scale (NIHSS)
Exclusion Criteria:
- Patients with a previous history of stroke affecting their upper limb will be excluded as a chronic limb condition from a previous stroke could affect the results
- Patients will also be excluded with peripheral nerve injury of the upper limb; an existing orthopaedic condition affecting the upper limb; fixed contractures at the elbow, wrist or fingers; malignancy in the area of the ES electrode placement; or epilepsy.
- Patients with a cardiac pacemaker or similar implanted device.
- Pregnancy
- Epilepsy
- Undiagnosed pain or skin conditions (i.e. not related to the stroke)
Carer participants for the main feasibility RCT eligibility criteria:
Inclusion Criteria:
- Nominated carer for a patient participating in the feasibility RCT
Exclusion Criteria:
- Non English speaking
Patient and carer interviews eligibility criteria:
Inclusion Criteria:
- Patients or carers who are participating in the main feasibility RCT
- mental capacity to consent and take part in the interview
- Able to understand English
Exclusion Criteria:
- Unable to communicate verbally or in written form
- Non-English speaking
- Aged younger than 18 years
Therapist Focus Discussion Groups:
Inclusion criteria:
- HCPC registered occupational therapist or physiotherapist
- Currently employed by NUH NHS Trust and working on the Nottingham Stroke Unit
- Experience of supporting at least one participant to use the ES intervention

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02324634
United Kingdom | |
Nottingham University Hospitals NUH Foundation Trust - Stroke Unit | |
Nottingham, Nottinghamshire, United Kingdom, NG16 1RS |
Principal Investigator: | Joanna C Fletcher-Smith, PhD; MPhil; BSc | University of Nottingham |
Responsible Party: | University of Nottingham |
ClinicalTrials.gov Identifier: | NCT02324634 |
Other Study ID Numbers: |
14110 |
First Posted: | December 24, 2014 Key Record Dates |
Last Update Posted: | May 5, 2017 |
Last Verified: | May 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Stroke Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Vascular Diseases Cardiovascular Diseases |